These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 33573372)
21. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913 [TBL] [Abstract][Full Text] [Related]
31. DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy. Sun L; Shen F; Xiong Z; Yang H; Dong Z; Xiang J; Gu Q; Ji Q; Fan C; Liu Z J Am Chem Soc; 2022 May; 144(17):7634-7645. PubMed ID: 35438987 [TBL] [Abstract][Full Text] [Related]
32. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells. East JE; Sun W; Webb TJ J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308 [TBL] [Abstract][Full Text] [Related]
33. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Steenblock ER; Fahmy TM Mol Ther; 2008 Apr; 16(4):765-72. PubMed ID: 18334990 [TBL] [Abstract][Full Text] [Related]
34. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses. Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399 [No Abstract] [Full Text] [Related]
35. Nanoparticle-based modulation of CD4 Isser A; Silver AB; Pruitt HC; Mass M; Elias EH; Aihara G; Kang SS; Bachmann N; Chen YY; Leonard EK; Bieler JG; Chaisawangwong W; Choy J; Shannon SR; Gerecht S; Weber JS; Spangler JB; Schneck JP Nat Commun; 2022 Oct; 13(1):6086. PubMed ID: 36241639 [TBL] [Abstract][Full Text] [Related]
36. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response. Lu X; Jiang X; Liu R; Zhao H; Liang Z Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475 [TBL] [Abstract][Full Text] [Related]
37. Harnessing Dendritic Cells for Poly (D,L-lactide- Koerner J; Horvath D; Groettrup M Front Immunol; 2019; 10():707. PubMed ID: 31024545 [TBL] [Abstract][Full Text] [Related]
38. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720 [TBL] [Abstract][Full Text] [Related]
39. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy. Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z Small; 2017 Oct; 13(40):. PubMed ID: 28861943 [TBL] [Abstract][Full Text] [Related]
40. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. Li H; Shao S; Cai J; Burner D; Lu L; Chen Q; Minev B; Ma W Immunology; 2017 Nov; 152(3):462-471. PubMed ID: 28664991 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]